Completed OBSERVATIONAL NCT06735300

Saliva PCR in Pregnant Women with COVID-19

Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Pregnant Women Treated with Nirmatrelvir/Ritonavir (Paxlovid) Using Saliva Polymerase Chain Reaction: a Prospective Cohort Study

Sponsor: National Cheng-Kung University Hospital

Conditions Coronavirus Disease 2019 (COVID-19) Pneumonia

Interventions Nirmatrelvir/Ritonavir (Paxlovid)

Updated 3 times since 2025 Last updated: Dec 11, 2024 Started: Jun 1, 2022 Primary completion: Oct 7, 2022 Completion: Oct 7, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Coronavirus Disease 2019 (COVID-19) Pneumonia and is currently completed. National Cheng-Kung University Hospital leads this study, which shows 3 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

3 versions recorded

Dec 2025 — Present [monthly]

Completed
Sep 2025 — Dec 2025 [monthly]

Completed
Jan 2025 — Sep 2025 [monthly]

Completed

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cheng-Kung University Hospital

Data source: National Cheng-Kung University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tainan, Taiwan